Cargando…

Metreleptin therapy in LMNA-linked lipodystrophies

Detalles Bibliográficos
Autores principales:	Vatier, Camille, Vigouroux, Corinne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652487/ http://dx.doi.org/10.1186/1750-1172-10-S2-O27

Ejemplares similares

Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes
por: Vatier, Camille, et al.
Publicado: (2019)

Looking at New Unexpected Disease Targets in LMNA-Linked Lipodystrophies in the Light of Complex Cardiovascular Phenotypes: Implications for Clinical Practice
por: Mosbah, Héléna, et al.
Publicado: (2020)

Metreleptin Treatment in Three Patients with Generalized Lipodystrophy
por: Musso, Carla, et al.
Publicado: (2017)

Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real‐life experience from a national reference network
por: Mosbah, Héléna, et al.
Publicado: (2022)

New advances in the treatment of generalized lipodystrophy: role of metreleptin
por: Rodriguez, Alexander J, et al.
Publicado: (2015)

Suggestive Evidence for an Antidepressant Effect of Metreleptin Treatment in Patients with Lipodystrophy
por: Vieira, Diana Branco, et al.
Publicado: (2022)

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
por: Saydam, O, et al.
Publicado: (2021)

Irisin levels in LMNA-mutated lipodystrophic syndromes
por: Bensmaine, Faiza, et al.
Publicado: (2015)

Molecular and Cellular Bases of Lipodystrophy Syndromes
por: Zammouri, Jamila, et al.
Publicado: (2022)

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
por: Nagayama, Ayako, et al.
Publicado: (2021)

Gene Therapy for LMNA-related Congenital Muscular Dystrophy (L-CMD) by Trans-Splicing
por: Azibani, Feriel, et al.
Publicado: (2015)

Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy
por: Jéru, Isabelle, et al.
Publicado: (2019)

Management of congenital muscular dystrophies related to defects in the LMNA gene
por: Quijano-Roy, Susana, et al.
Publicado: (2015)

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program
por: Ajluni, Nevin, et al.
Publicado: (2016)

Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin
por: Esfandiari, Nazanene H., et al.
Publicado: (2019)

OR17-02 Changes in Hepatokines and Apolipoproteins Are Associated with Metabolic Response to Metreleptin in Partial Lipodystrophy
por: Akinci, Baris, et al.
Publicado: (2020)

Metreleptin and Metformin Use in an Infant With Congenital Generalized Lipodystrophy Secondary to AGPAT2 Mutation
por: Schweisberger, Cintya, et al.
Publicado: (2021)

FRI056 Effect Of 48 Hour Of Metreleptin In Humans With Lipodystrophy During Controlled Feeding
por: Bukhari, Khulood M, et al.
Publicado: (2023)

SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023)

ECLip-the European consortium on lipodystrophies: an update
por: Araújo-Vilar, David
Publicado: (2015)

LMNA-associated myopathies: the Italian experience in a large cohort of patients
por: Maggi, Lorenzo
Publicado: (2015)

Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report
por: Takeyari, Shinji, et al.
Publicado: (2019)

Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report
por: Nagayama, Ayako, et al.
Publicado: (2019)

Metreleptin Robustly Increases Resting-state Brain Connectivity in Treatment-naïve Female Patients With Lipodystrophy
por: Schlögl, Haiko, et al.
Publicado: (2023)

SAT089 Natural History Of Generalized Lipodystrophy Following Early Vs. Late Metreleptin Treatment
por: Brush, Maiah, et al.
Publicado: (2023)

Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives
por: Vigouroux, Corinne, et al.
Publicado: (2018)

Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis
por: Sahinoz, Melis, et al.
Publicado: (2018)

Hepatic Steatosis Resulting From LMNA-Associated Familial Lipodystrophy
por: Mahdi, Layth, et al.
Publicado: (2020)

Partial Lipodystrophy and LMNA p.R545H Variant
por: Magno, Silvia, et al.
Publicado: (2021)

Peroxisome proliferator‐activated receptor gamma‐ligand‐binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration
por: Shoaito, Hussein, et al.
Publicado: (2020)

Possibilities, limits and particularities of plastic surgery treatment in HIV-associated lipodystrophy
por: Jianu, Dana, et al.
Publicado: (2014)

The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
por: Akinci, Baris, et al.
Publicado: (2020)

Novel Heterozygous LMNA Variants Causing Familial Partial Lipodystrophy, Dunnigan Variety
por: Wadhwa, Akhilesh, et al.
Publicado: (2021)

Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants
por: Vasandani, Chandna, et al.
Publicado: (2022)

SAT-081 Advanced Lipoprotein Analysis Demonstrates Atherogenic Lipid Profile in Patients with Lipodystrophy That Improves after Metreleptin Treatment
por: Kinzer, Alexandra, et al.
Publicado: (2019)

Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report
por: Pedicelli, Stefania, et al.
Publicado: (2020)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

Familial partial lipodystrophy and proteinuric renal disease due to a missense c.1045C > T LMNA mutation
por: Fountas, Athanasios, et al.
Publicado: (2017)

Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)
por: Montealegre, G, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bk522k0jjmg553nnh4prtmlup3